A Study of BMS-986207 Given Alone and in Combination With... | NCT02913313

ID	Type	Description	Link
2016-002263-34	EudraCT Number

Name	Class
Ono Pharmaceutical Co., Ltd.	INDUSTRY

Label	Type	Intervention Names
Part 1A: Dose Escalation Monotherapy	Experimental	Drug: BMS-986207
Part 1B: Dose Escalation Combination Therapy	Experimental	Drug: BMS-986207 Biological: Nivolumab
Part 2A: Expansion Monotherapy	Experimental	Drug: BMS-986207
Part 2B: Expansion Combination Therapy	Experimental	Drug: BMS-986207 Biological: Nivolumab
Part 1C: Triplet Cohort	Experimental	Drug: BMS-986207 Biological: Nivolumab Biological: Ipilimumab
Part 2C: Triplet Expansion	Experimental	Drug: BMS-986207 Biological: Nivolumab Biological: Ipilimumab

Name	Type	Description	Arm Group Labels	Other Names
BMS-986207	Drug	Specified dose on specified days	Part 1A: Dose Escalation Monotherapy Part 1B: Dose Escalation Combination Therapy Part 1C: Triplet Cohort

Measure	Description	Time Frame
Number of Participants With Adverse Events	An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.	From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)
Number of Participants Who Died	Participants who died with any cause are considered in the analysis.	From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)
Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities	Criteria for Dose-Limiting Toxicities (DLTs): Hepatic DLTs (excluding HCC): Grade (Gr) 4 elevations in AST, ALT, ALP, or total bilirubin. Gr 3 elevations in AST, ALT, or ALP >5 days, with symptoms, or bilirubin >2xULN without cholestasis. Gr 2 AST or ALT with symptomatic liver inflammation. AST or ALT >3xULN and bilirubin >2xULN without cholestasis. Hepatic DLTs for HCC: AST or ALT >10xULN for >2 weeks. AST or ALT >15xULN. Total bilirubin >8xULN (elevated at entry) or >5xULN (normal at entry). ALT ≥10xULN and bilirubin ≥2xULN or baseline, without other causes. Hematologic DLTs: Gr 4 neutropenia ≥7 days. Gr 4 thrombocytopenia. Gr 3 thrombocytopenia with bleeding or platelet transfusion. Febrile neutropenia. Gr 3 hemolysis requiring intervention. Gr 4 anemia not due to underlying disease. Dermatologic DLTs: Gr 4 rash. Gr 3 rash not improving to ≤Gr 1 after 1-2 week delay. Other DLTs: Gr 2-4 eye issues, Gr 3-4 toxicities, excluding specific Gr 3 events like nausea, fever.	From first dose (Day 1) and up to 6 weeks
Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities

Measure	Description	Time Frame
Objective Response Rate (ORR)	ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters

Name	Affiliation	Role
Bristol-Myers Squibb	Bristol-Myers Squibb	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Local Institution - 0001		Hackensack	New Jersey	07601	United States
Local Institution - 0003

Label	URL
BMS Clinical Trial Information	View source
BMS Clinical Trial Patient Recruiting	View source

ID	Title	Description
FG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
FG001	Part 1A BMS-986207 20 mg

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Jan 6, 2022

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants With Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

All Treated Participants.

Posted

Count of Participants

Participants

From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG003	Part 1A BMS-986207 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG004	Part 1A BMS-986207 800 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG005	Part 1A BMS-986207 1600 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w) or 2 doses of BMS-986207 administered every 4 weeks (q4w).
OG006	Part 2A BMS-986207 800 mg (CRC)	Participants with colorectal cancer (CRC) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG007	Part 1B BMS-986207 80 mg + Nivolumab 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w.
OG008	Part 1B BMS-986207 240 mg + Nivolumab 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w.
OG009	Part 1B BMS-986207 1600 mg + Nivolumab 480 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w.
OG010	Part 1B: BMS-986207 480 mg + Nivolumab 480 mg	Participants with CRC or ovarian cancer or hepatocellular carcinoma were administered with 480 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w.
OG011	Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with Nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and Ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the Nivolumab infusion.
OG012	Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.
OG013	Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.

Units	Counts
Participants	OG0001 OG0012 OG0023 OG003

Title

Denominators

Categories

Participants with any Adverse Events

Title	Measurements
	OG0001 OG0012 OG0023 OG003

Primary

Number of Participants Who Died

Participants who died with any cause are considered in the analysis.

All Treated Participants.

Posted

Count of Participants

Participants

From first dose (Day 1) untill 100 days after last dose (Up to approximately 27 months)

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).

Primary

Part 1A, 1B and 1C and 2A: Number of Participants With Dose Limiting Toxicities

Criteria for Dose-Limiting Toxicities (DLTs): Hepatic DLTs (excluding HCC): Grade (Gr) 4 elevations in AST, ALT, ALP, or total bilirubin. Gr 3 elevations in AST, ALT, or ALP >5 days, with symptoms, or bilirubin >2xULN without cholestasis. Gr 2 AST or ALT with symptomatic liver inflammation. AST or ALT >3xULN and bilirubin >2xULN without cholestasis. Hepatic DLTs for HCC: AST or ALT >10xULN for >2 weeks. AST or ALT >15xULN. Total bilirubin >8xULN (elevated at entry) or >5xULN (normal at entry). ALT ≥10xULN and bilirubin ≥2xULN or baseline, without other causes. Hematologic DLTs: Gr 4 neutropenia ≥7 days. Gr 4 thrombocytopenia. Gr 3 thrombocytopenia with bleeding or platelet transfusion. Febrile neutropenia. Gr 3 hemolysis requiring intervention. Gr 4 anemia not due to underlying disease. Dermatologic DLTs: Gr 4 rash. Gr 3 rash not improving to ≤Gr 1 after 1-2 week delay. Other DLTs: Gr 2-4 eye issues, Gr 3-4 toxicities, excluding specific Gr 3 events like nausea, fever.

All Treated Participants. Pre-specified to be only collected for Part 1A, 1B, 1C and 2A arms.

Posted

Count of Participants

Participants

From first dose (Day 1) and up to 6 weeks

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg

Primary

Part 1A, 1B and 1C and 2A: Number of Participants With Grade 3/Grade 4 Laboratory Abnormalities

Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening.

All treated participants with available laboratory abnormality results. Pre-specified to be only collected for Part 1A, 1B, 1C and 2A arms.

Posted

Count of Participants

Participants

From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months)

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 80 mg

Primary

Part 2C: Objective Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

All Treated Participants.

Posted

Number

95% Confidence Interval

percentage of participants

From first dose (Day 1) and up to 24 weeks

ID	Title	Description
OG000	Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.

Units	Counts
Participants

Primary

Part 2C: Duration of Response (DOR)

DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

All Treated Participants. Participants with CR or PR were included in the analysis.

Posted

Median

Full Range

months

From first dose (Day 1) and up to 24 weeks

ID	Title	Description
OG000	Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.

Units	Counts
Participants

Primary

Part 2C: Progression Free Survival Rate at Week 24

Progression Free Survival Rates at 24 weeks is defined as the percentage of participants who achieve PFS at 24 weeks. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates.

Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

All Treated Participants.

Posted

Number

95% Confidence Interval

percentage of participants

Week 24

ID	Title	Description
OG000	Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.

Secondary

Objective Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters

All Treated Participants.

Posted

Number

95% Confidence Interval

percentage of participants

From first dose (Day 1) and up to 24 weeks

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 80 mg

Secondary

Duration of Response

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

All Treated Participants. Participants with CR or PR were included in the analysis.

Posted

Median

Full Range

percentage of participants

From first dose (Day 1) and up to 24 weeks

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002

Secondary

Progression Free Survival Rate at Week 24

All Treated Participants.

Posted

Number

95% Confidence Interval

percentage of participants

Week 24

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).

Secondary

Maximum Observed Concentration (Cmax) of BMS-986207

Cmax is defined as maximum plasma concentration of the drug.

All treated participants who have evaluable concentration-time data were included in the analysis. Only participants with evaluable concentration-time data at particular timepoint are considered in the analysis. Participant in Part 1A BMS-986207 Safety Run In did not meet criteria of evaluable concentration-time data hence not included in the analysis.

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 240 mg

Secondary

BMS-986207 Time to Maximum Concentration (Tmax)

Time to observed maximum concentration (Tmax) is defined as the amount of time in hours for a drug to reach the maximum concentration after administration.

Posted

Geometric Mean

Geometric Coefficient of Variation

hours

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).

Secondary

BMS-986207 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T))

BMS-986207 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).

Posted

Geometric Mean

Geometric Coefficient of Variation

h*ng/mL

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).

Secondary

BMS-986207 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU)

Blood samples were collected for assessing AUC (TAU).

Posted

Geometric Mean

Geometric Coefficient of Variation

h*ng/mL

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002

Secondary

BMS-986207 Observed Serum Concentration at the End of a Dosing Interval (Ctau)

Blood samples were collected for assessing Ctau.

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002

Secondary

BMS-986207 Total Body Clearance (CLT)

Blood samples were collected for assessing CLT.

Posted

Geometric Mean

Geometric Coefficient of Variation

L/h

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 240 mg

Secondary

BMS-986207 Average Concentration Over a Dosing Interval (Css-avg)

Blood samples were collected for assessing Css-avg.

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002

Secondary

BMS-986207 Ratio of an Exposure Measure at Steady State to That After the First Dose (AI_TAU)

Blood samples were collected for assessing AI_TAU.

Posted

Geometric Mean

Geometric Coefficient of Variation

Ratio

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002

Secondary

BMS-986207 Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (T-HALFeff)

Blood samples were collected for assessing T-HALFeff. Exposure measure includes AUC[TAU].

Posted

Geometric Mean

Geometric Coefficient of Variation

hours

Day 1 of Cycle 1, Cycle 2 and Cycle 3 (Each cycle is of 8 weeks)

ID	Title	Description
OG000	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG001	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).

Secondary

Number of Participants With Positive Anti-BMS-986207-Antibodies Results

Participants who were treated with BMS-986207 and at least one post-baseline evaluable ADA assessment were considered in the analysis

All Treated Participants with Baseline and at Least One Post-baseline Evaluable ADA Assessment were included in the analysis.

Posted

Count of Participants

Participants

From first dose (Day 1) till 100 days after last dose (Up to approximately 27 months)

ID	Title	Description
OG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
OG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
OG002	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Atrial fibrillation	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG0030 affected4 at risk EG0040 affected8 at risk EG0050 affected4 at risk EG0060 affected20 at risk EG0070 affected4 at risk EG0080 affected4 at risk EG0090 affected4 at risk EG0101 affected18 at risk EG0110 affected6 at risk EG0120 affected18 at risk EG0130 affected5 at risk
Atrioventricular block complete	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Cardiac tamponade	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Myocarditis	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Adrenal insufficiency	Endocrine disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Inappropriate antidiuretic hormone secretion	Endocrine disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Exophthalmos	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Abdominal pain	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Abdominal pain lower	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Enterocolitis	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Gastrointestinal haemorrhage	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Intestinal obstruction	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Rectal haemorrhage	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Small intestinal obstruction	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pyrexia	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Bile duct stenosis	Hepatobiliary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyperbilirubinaemia	Hepatobiliary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Jaundice cholestatic	Hepatobiliary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Allergic oedema	Immune system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypersensitivity	Immune system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Bacteraemia	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Cellulitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Encephalitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumococcal sepsis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumonia	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumonia aspiration	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Septic shock	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Stoma site cellulitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Urinary tract infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vascular device infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Wound infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Fall	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Aspartate aminotransferase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood alkaline phosphatase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood bilirubin increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Muscular weakness	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Brain cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Colorectal adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Colorectal cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hepatocellular carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Malignant neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0001 affected1 at risk EG0010 affected2 at risk EG0022 affected3 at risk EG003
Metastases to central nervous system	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Epilepsy	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Spinal cord compression	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Syncope	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vocal cord paralysis	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumonitis	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pulmonary haemorrhage	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dermatitis bullous	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Embolism	Vascular disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0021 affected3 at risk EG0031 affected4 at risk EG0042 affected8 at risk EG0052 affected4 at risk EG0063 affected20 at risk EG0071 affected4 at risk EG0082 affected4 at risk EG0092 affected4 at risk EG0103 affected18 at risk EG0113 affected6 at risk EG0123 affected18 at risk EG0134 affected5 at risk
Iron deficiency anaemia	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Leukocytosis	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Leukopenia	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Neutropenia	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pernicious anaemia	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Splenomegaly	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Thrombocytopenia	Blood and lymphatic system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Atrial fibrillation	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Bradycardia	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Myocarditis	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Sinus tachycardia	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Tachycardia	Cardiac disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Ear pruritus	Ear and labyrinth disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Adrenal insufficiency	Endocrine disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyperthyroidism	Endocrine disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypothyroidism	Endocrine disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Conjunctival haemorrhage	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Ocular hyperaemia	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Periorbital oedema	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Periorbital swelling	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vision blurred	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Visual impairment	Eye disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Abdominal distension	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Abdominal pain	Gastrointestinal disorders	26.1	Systematic Assessment	EG0001 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Aptyalism	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Ascites	Gastrointestinal disorders	26.1	Systematic Assessment	EG0001 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Constipation	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Diarrhoea	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Dry mouth	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dyspepsia	Gastrointestinal disorders	26.1	Systematic Assessment	EG0001 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dysphagia	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Flatulence	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Frequent bowel movements	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Gastrointestinal pain	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Gastrooesophageal reflux disease	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Nausea	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Oesophageal rupture	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Oesophagitis	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Oesophagomediastinal fistula	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Oral pain	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Proctalgia	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Rectal haemorrhage	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Salivary duct inflammation	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Stomatitis	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vomiting	Gastrointestinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Asthenia	General disorders	26.1	Systematic Assessment	EG0001 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Chills	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Fatigue	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Gait disturbance	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Influenza like illness	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Localised oedema	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Malaise	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Multiple organ dysfunction syndrome	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Nodule	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Non-cardiac chest pain	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Oedema peripheral	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Pain	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Peripheral swelling	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pyrexia	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Swelling face	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vessel puncture site erythema	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Xerosis	General disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hepatic function abnormal	Hepatobiliary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Portal vein thrombosis	Hepatobiliary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Bronchitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
COVID-19	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
COVID-19 pneumonia	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Cellulitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Cryptosporidiosis infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Encephalitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Eye infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Herpes zoster	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Localised infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Lower respiratory tract infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Nasopharyngitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Oral candidiasis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Paronychia	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pharyngitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumonia	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumonia bacterial	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Skin infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Stoma site abscess	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Stoma site cellulitis	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Stoma site infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Upper respiratory tract infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Urinary tract infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Wound infection	Infections and infestations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Eye contusion	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Fall	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hand fracture	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Infusion related reaction	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Procedural pain	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Radiation skin injury	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Tooth fracture	Injury, poisoning and procedural complications	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Adjusted calcium increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Alanine aminotransferase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Ammonia increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Amylase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Aspartate aminotransferase decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Aspartate aminotransferase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood albumin decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood alkaline phosphatase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Blood bilirubin increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood calcium increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood cholesterol increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood creatinine increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood glucose increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood lactate dehydrogenase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood magnesium decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood potassium decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Blood sodium decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood testosterone decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood thyroid stimulating hormone decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood thyroid stimulating hormone increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Blood urea increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Blood uric acid increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Drug level increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Gamma-glutamyltransferase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
International normalised ratio increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Lipase decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Lipase increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Lymphocyte count decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Lymphocyte count increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Neutrophil count decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Neutrophil count increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Platelet count decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Protein total decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Troponin increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Weight decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Weight increased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
White blood cell count decreased	Investigations	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Acidosis	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dehydration	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Glucose tolerance impaired	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypercalcaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Hyperglycaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyperkalaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Hyperphosphataemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyperuricaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypoalbuminaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Hypocalcaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypokalaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Hypomagnesaemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0001 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypophosphataemia	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Malnutrition	Metabolism and nutrition disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Arthritis	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Bone pain	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Exostosis	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Flank pain	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Greater trochanteric pain syndrome	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Joint range of motion decreased	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Joint swelling	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Muscular weakness	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Neck pain	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Spinal pain	Musculoskeletal and connective tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Cancer pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Colorectal cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Laryngeal papilloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Peritumoural oedema	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Aphasia	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Ataxia	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Brain oedema	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Disturbance in attention	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dizziness	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Drooling	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Headache	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hemiparesis	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Lethargy	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Neuropathy peripheral	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Paraesthesia	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Parkinsonism	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Peripheral sensory neuropathy	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Sensory disturbance	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Somnolence	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Taste disorder	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Tremor	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Ulnar nerve palsy	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vocal cord paralysis	Nervous system disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Affective disorder	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Anxiety	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Confusional state	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Delirium	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Depression	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hallucination	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Insomnia	Psychiatric disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Acute kidney injury	Renal and urinary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dysuria	Renal and urinary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pollakiuria	Renal and urinary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Proteinuria	Renal and urinary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Urinary incontinence	Renal and urinary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Urogenital fistula	Renal and urinary disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0021 affected3 at risk EG003
Dyspnoea exertional	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Epistaxis	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Haemoptysis	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hiccups	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypoxia	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Laryngeal inflammation	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Nasal congestion	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Pleural effusion	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Pneumonitis	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pneumothorax	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Productive cough	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Respiratory failure	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Sneezing	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Stridor	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Throat irritation	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Tracheal fistula	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Wheezing	Respiratory, thoracic and mediastinal disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dermatitis acneiform	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dermatitis allergic	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dermatitis bullous	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dermatitis contact	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Dry skin	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Erythema	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hyperkeratosis	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Night sweats	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pain of skin	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Purpura	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Rash	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0011 affected2 at risk EG0020 affected3 at risk EG003
Rash macular	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Rash maculo-papular	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Rash papular	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Skin lesion	Skin and subcutaneous tissue disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0021 affected3 at risk EG003
Embolism	Vascular disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypertension	Vascular disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Hypotension	Vascular disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003
Vasculitis	Vascular disorders	26.1	Systematic Assessment	EG0000 affected1 at risk EG0010 affected2 at risk EG0020 affected3 at risk EG003

ID	Term
D061067	Antibodies, Monoclonal, Humanized
D000911	Antibodies, Monoclonal
D000906	Antibodies
D007136	Immunoglobulins
D007162	Immunoproteins
D001798	Blood Proteins
D011506	Proteins
D000602	Amino Acids, Peptides, and Proteins
D012712	Serum Globulins
D005916	Globulins

ID	Title	Description
BG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).
BG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
BG002	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
BG003	Part 1A BMS-986207 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
BG004	Part 1A BMS-986207 800 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
BG005	Part 1A BMS-986207 1600 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w) or 2 doses of BMS-986207 administered every 4 weeks (q4w).
BG006	Part 2A BMS-986207 800 mg (CRC)	Participants with colorectal cancer (CRC) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).
BG007	Part 1B BMS-986207 80 mg + Nivolumab 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w.
BG008	Part 1B BMS-986207 240 mg + Nivolumab 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w.
BG009	Part 1B BMS-986207 1600 mg + Nivolumab 480 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w.
BG010	Part 1B: BMS-986207 480 mg + Nivolumab 480 mg	Participants with CRC or ovarian cancer or hepatocellular carcinoma were administered with 480 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w.
BG011	Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with Nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and Ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the Nivolumab infusion.
BG012	Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.
BG013	Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.
BG014	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Part 1A BMS-986207 Safety Run In	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with total 48 mg of BMS-986207 as 60 minutes intravenous infusion in one cycle (each cycle of 8 weeks).	1	1	1	1	1	1
EG001	Part 1A BMS-986207 20 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 20 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).	0	2	0	2	2	2
EG002	Part 1A BMS-986207 80 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).	3	3	3	3	3	3
EG003	Part 1A BMS-986207 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).	2	4	3	4	4	4
EG004	Part 1A BMS-986207 800 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).	5	8	5	8	8	8
EG005	Part 1A BMS-986207 1600 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w) or 2 doses of BMS-986207 administered every 4 weeks (q4w).	2	4	1	4	4	4
EG006	Part 2A BMS-986207 800 mg (CRC)	Participants with colorectal cancer (CRC) were administered with 800 milligram of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every 2 weeks (q2w).	15	20	11	20	20	20
EG007	Part 1B BMS-986207 80 mg + Nivolumab 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 80 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w.	2	4	3	4	3	4
EG008	Part 1B BMS-986207 240 mg + Nivolumab 240 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 240 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered every q2w. Participants were also administered with Nivolumab 240 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q2w.	4	4	2	4	4	4
EG009	Part 1B BMS-986207 1600 mg + Nivolumab 480 mg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w.	4	4	1	4	4	4
EG010	Part 1B: BMS-986207 480 mg + Nivolumab 480 mg	Participants with CRC or ovarian cancer or hepatocellular carcinoma were administered with 480 mg of BMS-986207 as 60 minutes intravenous infusion for up to maximum of 6 cycles (each cycle is of 8 weeks). Each cycle comprise 4 doses of BMS-986207 administered q4w. Participants were also administered with Nivolumab 480 mg as 60 minutes intravenous infusion for up to maximum of 6 cycles and each cycle comprise 4 doses of Nivolumab administered q4w.	7	18	6	18	18	18
EG011	Part 1C BMS-986207 1200 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 1600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with Nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and Ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the Nivolumab infusion.	3	6	4	6	6	6
EG012	Part 1C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with advanced solid tumors (metastatic, recurrent and/or unresectable) were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.	13	18	11	18	18	18
EG013	Part 2C BMS-986207 600 mg + Nivolumab 360 mg + Ipilimumab 1 mg/kg	Participants with first-line non-small cell lung cancer were administered with 600 mg of BMS-986207 every 3 weeks (q3w) as 60 minutes intravenous infusion for up to PD, unacceptable toxicity, or other protocol defined reasons or maximum of 2 years. Participants were also administered with nivolumab 360 mg as 60 minutes intravenous infusion every 3 weeks (q3w) and ipilimumab 1 mg/kg as intravenous infusion every 6 weeks at least 30 minutes after completion of the nivolumab infusion.	3	5	5	5	5	5